In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...